Available Treatment

Until recently, the only treatment approved by the Food and Drug Administration for patients with chronic hepatitis was interferon monotherapy. A major step forward in the treatment of patients with chronic hepatitis C is REBETRON™ Combination Therapy containing REBETOL® (Ribavirin, USP) Capsules and INTRON® A (Interferon alfa-2b, recombinant) for Injection. This combination therapy consists of interferon and an antiviral agent, ribavirin.

Treatment for Chronic Hepatitis B

INTRON® A (Interferon alfa-2b) for Injection is indicated for the initial therapy of appropriate chronic hepatitis B patients.

To be eligible for interferon alfa-2b treatment, chronic hepatitis B patients must be at least 1 year old and have been HBsAg-positive for at least 6 months, with elevated serum ALT levels, and HBV replication as determined by the presence of HBeAg in serum. Other selection criteria include the presence of compensated liver disease and a liver biopsy consistent with chronic hepatitis B.

For more information about INTRON® A, see the section, "INTRON A Therapy."

Treatment for Chronic Hepatitis C

  • REBETRON™ Combination Therapy containing REBETOL® (Ribavirin, USP) Capsules and INTRON® A (Interferon alfa-2b, recombinant) Injection
    REBETRON Combination Therapy is indicated for the initial treatment of chronic hepatitis C in patients with compensated liver disease or in patients who have not maintained a response following alpha interferon monotherapy.


    Prior to the availability of REBETRON Combination Therapy, the only drugs approved in the United States for treating hepatitis C had been alfa interferons.


    Suitable chronic hepatitis C patients are 18 years or older with compensated liver disease.


    For more information, see the section, "REBETRON™ Combination Therapy."
  • INTRON® A (Interferon alfa-2b, recombinant) for Injection
    INTRON® A is indicated for the initial treatment of chronic hepatitis C patients. The best treatment results with INTRON® A were obtained in circumstances that included the following patient factors:


    –HCV genotype other than type I
    –Low pretreatment HCV RNA levels
    –Absence of cirrhosis
    –Low hepatic iron concentration
    –Younger age
    –Short disease duration


For more information, see the section, "INTRON A Therapy."

4 of 11






Terms and Conditions | Privacy Policy | Important Safety Information